The type 1 diabetes consensus 2026 expands guidance on AID, cardiovascular risk, obesity, complications, psychosocial care, and new therapies.
Read More »Pump or Smart Pen? A Head-to-Head Trial Finds There May Be More Than One Right Answer
A head-to-head trial compared a smart insulin pen vs AID in adults with type 1 diabetes. See who benefited most and why patient preference still matters.
Read More »Sex and Blood Sugar: Does Intimacy Put People With Type 1 Diabetes at Risk for Hypoglycemia?
A small CGM study explores whether sexual activity increases hypoglycemia risk in adults with type 1 diabetes and what the findings mean for care.
Read More »Eat, Then Exercise—or Exercise First? In Type 1 Diabetes, the Order May Matter
Discover how exercise timing in type 1 diabetes, meal timing, insulin on board, and workout intensity can influence glucose responses.
Read More »Teplizumab Has Competition: A Head-to-Head Trial Could Reshape Type 1 Diabetes Prevention
TrialNet’s ASCEND T1D trial compares ATG with teplizumab to explore new ways to delay progression of Stage 2 type 1 diabetes.
Read More »Fasting With Type 1 Diabetes? A New Trial Puts Time-Restricted Eating to the Test
Time-restricted eating has become a popular approach to weight management, but what happens when insulin-dependent diabetes enters the picture? Until recently, evidence on time-restricted eating in people with type 1 diabetes was notably limited. A new randomized controlled trial published in Diabetes Care offers some of the first direct evidence. …
Read More »Could CGM Help People With Type 1 Diabetes Live Longer?
Could continuous glucose monitoring do more than improve glucose levels and help prevent hypoglycemia? New research raises that possibility. A large observational study examining CGM use and mortality in people with type 1 diabetes found that starting continuous glucose monitoring was associated with a lower risk of death among older …
Read More »When “Normal” Blood Sugar Feels Too Low: New Research May Explain Why
When glucose numbers improve, patients are expected to feel better. Yet some people with type 1 diabetes report the opposite. A glucose level that looks reassuring on a continuous glucose monitor may leave them feeling tired, uncomfortable, or simply “off.” New research suggests that glycemic habituation may help explain this …
Read More »SGLT Inhibitors Protect the Heart and Kidneys: Why Is Type 1 Diabetes Still the Exception?
SGLT inhibitors have changed the treatment landscape for cardiovascular and kidney disease, particularly in people with type 2 diabetes, heart failure, and chronic kidney disease. That success raises an obvious question: why are SGLT inhibitors in type 1 diabetes still largely outside routine clinical practice? The answer is not a …
Read More »Three Decades of Better Type 1 Diabetes Care: Have Complications Actually Declined?
Three decades of advances in diabetes care have transformed how people with type 1 diabetes manage glucose. Insulin pumps, continuous glucose monitoring (CGM), improved insulin analogs, automated insulin delivery, and earlier screening have all changed daily treatment. However, have these advances actually reduced the long-term complications of type 1 diabetes? …
Read More »
Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.